How to buy Moleculin Biotech stock (MBRX)

Moleculin Biotech is a biotechnology business based in the US. Moleculin Biotech shares (MBRX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.88 – a decrease of 23.58% over the previous week. Moleculin Biotech employs 18 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Moleculin Biotech stock

Buy Moleculin Biotech stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Moleculin Biotech stock price (NASDAQ: MBRX)

Use our graph to track the performance of MBRX stocks over time.

Moleculin Biotech shares at a glance

• Key figures

Information last updated 2024-12-12.

Latest market close	$1.88
52-week range	$2.12 - $15.75
50-day moving average more info button	$2.56
200-day moving average more info button	$3.20
Wall St. target price	$18.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-12.04

Is it a good time to buy Moleculin Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Moleculin Biotech price performance over time

Historical closes compared with the close of $1.86 from 2024-12-17

1 week (2024-12-12)	-24.39%
1 month (2024-11-19)	-28.87%
3 months (2024-09-19)	-24.39%
6 months (2024-06-18)	-53.27%

1 year (2023-12-19)	165.71%
2 years (2022-12-19)	-90.08%
3 years (2021-12-17)	32.1
5 years (2019-12-19)	89.1

Moleculin Biotech financials

Gross profit TTM	$0
Return on assets TTM	-57.45%
Return on equity TTM	-141.49%
Profit margin	0%
Book value	$3.36
Market Capitalization more info button	$8 million

TTM: trailing 12 months

Moleculin Biotech share dividends

We're not expecting Moleculin Biotech to pay a dividend over the next 12 months.

Have Moleculin Biotech's shares ever split?

Moleculin Biotech's shares were split on a 1:15 basis on 21 March 2024 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Moleculin Biotech shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Moleculin Biotech shares which in turn could have impacted Moleculin Biotech's share price.

Moleculin Biotech share price volatility

Over the last 12 months, Moleculin Biotech's shares have ranged in value from as little as $2.115 up to $15.75. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moleculin Biotech's is 1.858. This would suggest that Moleculin Biotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Moleculin Biotech overview

Moleculin Biotech, Inc. , a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas. .

Frequently asked questions

What percentage of Moleculin Biotech is owned by insiders or institutions?
Currently 3.34% of Moleculin Biotech shares are held by insiders and 15.342% by institutions. How many people work for Moleculin Biotech?
Latest data suggests 18 work at Moleculin Biotech. When does the fiscal year end for Moleculin Biotech?
Moleculin Biotech's fiscal year ends in December. Where is Moleculin Biotech based?
Moleculin Biotech's address is: 5300 Memorial Drive, Houston, TX, United States, 77007 What is Moleculin Biotech's ISIN number?
Moleculin Biotech's international securities identification number is: US60855D2009 What is Moleculin Biotech's CUSIP number?
Moleculin Biotech's Committee on Uniform Securities Identification Procedures number is: 60855D101